GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer

Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts

(2009) C. L. Roland et al.   MOLECULAR CANCER THERAPEUTICS

Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer

(2009) Christina L. Roland et al.   PLoS One

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

(2008) M. E. Lacouture et al.   ANNALS OF ONCOLOGY

The pharmacophore of a peptoid VEGF receptor 2 antagonist includes both side chain and main chain residues

(2008) D. Gomika Udugamasooriya et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Vascular Endothelial Growth Factor Receptor 2 Mediates Macrophage Infiltration into Orthotopic Pancreatic Tumors in Mice

(2008) S. P. Dineen et al.   CANCER RESEARCH

A VEGFR2 Antagonist and Other Peptoids Evade Immune Recognition

(2008) John M. Astle et al.   International Journal of Peptide Research and Therapeutics

A Peptoid “Antibody Surrogate” That Antagonizes VEGF Receptor 2 Activity

(2008) D. Gomika Udugamasooriya et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS